Definium Therapeutics (DFTX) Redefines Depression & Anxiety Treatment

Meridian Small Cap Growth Fund's Q2 2026 investor letter highlighted Definium Therapeutics (NASDAQ:DFTX), a biopharmaceutical company developing a single-dose LSD-based therapy for major depressive disorder and generalized anxiety disorder. The company reported positive topline results from its pivotal Phase 3 study, exceeding investor-set efficacy benchmarks with durable treatment effects and high remission rates versus placebo. This success significantly de-risked the program and set the stage for the first generalized anxiety disorder readout. DFTX, with a $5.6 billion market cap, surged 363.81% over 52 weeks. Meridian Fund emphasized its potential to lead in large, underserved mental health markets and its pipeline approaching pivotal readouts. How will markets react to this breakthrough?